Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Palbociclib + SGI-1776|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Palbociclib||Ibrance||PD0332991||CDK4/6 Inhibitor 11||Ibrance (palbociclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) (PMID: 19874578). Ibrance (palbociclib) is approved in combination with an aromatase inhibitor in postmenopausal patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer, and in combination with Faslodex (fulvestrant) in patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer (FDA.gov).|
|SGI-1776||PIM Inhibitor (Pan) 9||SGI-1776 is a small molecule inhibitor of PIMs 1, 2, 3, and FLT-3, which may result in cell death via indirect inhibition of Mcl-1 transcription and protein synthesis (PMID: 21628411, PMID: 32558942).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 act mut||acute myeloid leukemia||sensitive||Palbociclib + SGI-1776||Preclinical||Actionable||In a preclinical study, Ibrance (palbociclib) and SGI-1776 were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).||27099147|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|